Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Multiple Sclerosis Related Urge Incontinence

Not Applicable

Recruiting

• Conditions: Multiple Sclerosis
• Interventions: Other: Stoller's Afferent Nerve Stimulation (SANS)

• Registration Number: NCT06314412
• Lead Sponsor: Istituto Auxologico Italiano

Brief Summary

Recently, several studies have investigated the safety and efficacy of the Stoller afferent nerve stimulation (SANS) treatment in Multiple Sclerosis (MS) patients. However, because of the differences among the published protocols (percutaneous versus transcutaneous stimulation, stimulation site, total number of sessions), and the absence of data on the duration of the effect, this treatment is not yet currently included in the rehabilitation programs. The present study aims at evaluating the efficacy of a protocol of SANS in the short- and medium-term follow-up.

The efficacy of the proposed stimulation protocol on the physiological parameters of bladder function will be also investigated.

Detailed Description

The primary outcome will be the variation of urinary urgency and incontinence. It will be evaluated by self-reported measuring scales, such as the Overactive Bladder Questionnaire (OAB-q) and the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) in their Italian forms.

The expected outcome is that the treatment of posterior tibial nerve stimulation will reduce the frequency and the urgency of urination, and urinary incontinence. Moreover, results from the follow-up will allow estimating the duration of the expected outcome.

Study Timeline

• Study Start: 2023-02-13
• Status Verified: 2024-03
• Study First Submitted: 2024-03-04
• Study First Submitted QC: 2024-03-13
• Last Update Submitted: 2024-03-13
• Study First Posted: 2024-03-18
• Last Update Posted: 2024-03-18
• Primary Completion: 2025-04
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• MS diagnosis according to the revised McDonalds criteria. Relapsing-remitting, primary and secondary progressive MS forms are allowed;
• Expanded Disability Status Scale (EDSS) between 2 and 6.5 included;
• MiniMental State Examination ≥ cut off 24/84 by sex/age

Exclusion criteria:

• Any of the following in the month before enrolment: an MS relapse; current corticosteroids therapy because of MS; change in medicines prescribed against fatigue; attending an intensive physical therapy program;
• New or active lesions on a brain or spinal cord MRI scan in the 12 months before the study enrolment;
• Any musculoskeletal disease or any additional neurological disorder
• Urinary infections or surgery in perineal regions
• Skin lesions or carcinoma in situ
• Pregnancy
• Expanded Disability Status Scale (EDSS) ≥ 7;

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients with Multiple Sclerosis	Stoller's Afferent Nerve Stimulation (SANS)	Patients with Multiple Sclerosis

Primary Outcome Measures

Name	Time	Method
Measure of variation of urinary urgency	Baseline, at 3 weeks after the start of SANS, at 2 months after the end of SANS	Evaluated by the Overactive Bladder Questionnaire (OAB-q) in the Italian language.
Measure of variation of incontinence.	Baseline, at 3 weeks after the start of SANS, at 2 months after the end of SANS	Evaluated by the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) in the Italian language.

Trial Locations

Locations (1)

Istituto Auxologico Italiano; 🇮🇹 Milan, Italy